Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoyl group to improve stability
PubChem lists GHK-Cu as a copper-containing compound and identifies glycyl-L-histidyl-L-lysine as the parent compound in the record [1] [2]
What exactly makes them different
Neuropathic pain: It has been studied for its ability to reduce nerve pain and improve sensory recovery in nerve injury and diabetic neuropathy models (Gavrilovic et al., 2016)
What community members commonly report: Injection-site reactions (redness, swelling) expected with large-volume subcutaneous injections Mild flu-like symptoms in the 24-72 hours following injection, which some interpret as an immune response to senescent cell die-off Fatigue and general malaise lasting 1-3 days post-injection No noticeable positive effects yet What community members probably will NOT notice: Improved energy or vitality Visible changes in skin, hair, or physical appearance Measurable changes in bloodwork Any performance enhancement Realistic expectation: Week 1 is about initiating the senolytic process
The amino acid sequence is in the public domain and there is no composition-of-matter patent worth pursuing, so no commercial sponsor will fund the hundreds of millions a Phase IIIII development programme costs for a compound it cannot exclusively monetise
